Background {#Sec1}
==========

Chronic Non-bacterial Osteomyelitis (CNO) is a rare inflammatory disorder that is characterized by onset of pain, local bone expansion and radiological findings suggestive of osteomyelitis, usually at multiple sites, not related to an infectious disease \[[@CR1]\]. Although its pathogenesis remains still unknown, there is consensus about the hypothesis that CNO might be a genetic disease within the spectrum of autoinflammatory disorders \[[@CR2]--[@CR4]\]. Although the existence of genes contributing to sporadic CNO has been proposed, their identification is still missing \[[@CR5]\].

Cox et al have recently demonstrated that *FBLIM1*, a gene that codes for a protein involved in the regulation of bone remodeling, could be involved in the pathogenesis of sterile bone inflammation. The authors, via whole-exome sequencing, detected a homozygous mutation in the filamin-binding domain of *FBLIM1* in an affected child with consanguineous parents. They also sequenced *FBLIM1* in 96 subjects with CNO and found a second patient with a distinct frameshift variant \[[@CR6]\].

On this basis, we sequenced the *FBLIM1* gene in a cohort of Italian patients with CNO and correlated the results with clinical manifestations.

Methods {#Sec2}
=======

This is a multicenter observational study. In the absence of validated international diagnostic criteria, we used the proposed Jansson criteria for CNO diagnosis \[[@CR7]\]. The clinical and radiological data were entered into a customized and anonymized database and considered as variables for correlation analysis. Blood samples were collected from patients affected by CNO from 7 Italian rheumatology centers: IRCCS Burlo Garofolo, Trieste; Spedali Civili, Brescia; Anna Meyer Children's Hospital, Florence; Bambino Gesù Children's Hospital, Rome; G. Di Cristina Children's Hospital, Palermo; "Giovanni XXIII" Pediatric Hospital, Bari and IRCCS Giannina Gaslini, Genoa. Written informed parental consent, according to the approved protocol of the IRCCS "Burlo Garofolo" ethics committee (n°27/14) was obtained for genetic analysis. Blood collected for DNA analysis was taken specifically for this study during a routine blood sampling. After standard genomic isolation, DNA was used for Sanger sequencing on entire coding and flanking regions of *FBLIM1*. All sequences were analyzed with codon code aligner software (V.7.1.1 version). Only rare (global MAF \< 2%), coding variants detected were considered. To predict if each variation could be harmful for the protein function, we used the following softwares: Polyphen2 (<http://genetics.bwh.harvard.edu/pph2/>); SIFT (<http://sift.jcvi.org>); MUTATION ASSESSOR (<http://mutationassessor.org/r3/>); Human Splicing Finder (<http://www.umd.be/HSF/>) and TRANSFAC (<http://gene-regulation.com/pub/databases.html#transfac>). Controls were taken from the gnomAD, a worldwide database of hundreds of thousands of individuals with no manifested pathologies, stratified by regions of origin.

Clinical evaluation between patients with and without rare variants was performed. Fisher' s exact test was used to compare categorical and ordinal data, and Student's t test was used to analyze continuous data.

Results {#Sec3}
=======

Eighty patients diagnosed with CNO were enrolled, 52 females (65%) and 28 males (35%). Bone pain was the most common clinical complaint; median age at onset was 9 years (range 4--14 years). We found a median number of six bone localizations per patient; 9 patients had a single lesion. Most lesions were located to the long bones (65%), pelvis (48%) and spine (37%). Three patients presented skull lesions (they underwent bone biopsy to exclude malignancy). Five patients (5.8%) had a first-degree relative affected by an autoimmune disorder. Thirty patients (35%) had a comorbidity; among these, 18 (22.5%) had skin manifestations such as psoriasis, pustulosis or severe acne, 4 (5%) had inflammatory bowel disease. No consanguinity nor family history for CNO was reported.

Sanger sequencing was conducted in all patients. 18 out of 80 (22,5%) patients presented at least one rare (≤ 0.02) variant in *FBLIM1* gene. In particular, 15 patients presented 1 rare variant; 2 patients presented 2 rare variants and 1 patient had 5 rare variants. In total, 11 rare variants were found (7 out of 11 variants presented a MAF ≤ 0.01).

Table [1](#Tab1){ref-type="table"} displays the variants /SNPs identified. 5 out of 11 variants were in the coding regions and 6 were intronic. Among the SNP in the coding region 3 are missense and 2 synonymous variants. Two of the missense (Arg38Gln and Gly311Arg) and one of the intronic variants (c.250 + 32 C \> A) have been previously reported in CNO by Cox et al \[[@CR9]\]. The other eight variants have never been associated with CNO. Table 1Rare variants of *FBLIM1* gene identified in 18 patients affected by Chronic Non-Bacterial OsteomyelitisrsChangeAmino acid changesMAFVariantPatients**1**rs540511146c.65G \> Ap.Arg22HisA = 0.00011missenseP12**2**rs201006671c.-20-49G \> TN/AT = 0.0033intronP18**3**rs76050903c.-20-48C \> AN/AA = 0.0033intronP18**4**rs146575757^a^c.113G \> Ap.Arg38GlnA = 0.00391missenseP18**5**rs61733331c.222G \> Ap.Pro74=A = 0.00675synonymousP18**6**rs766409425c.541 + 13G \> AN/AA = 0.00003intronP7**7**rs187479896c.717 + 14A \> GN/AG = 0.00083intronP13**8**rs41310367 ^a^c.250 + 32C \> AN/AT = 0.0191intronP3; P11**9**rs140170023c.447G \> Ap.Ala149=A = 0.01200synonymousP2, P3, P4, P5, P6, P8, P9, P10, P13, P15**10**rs114077715 ^a^c.931G \> Ap.Gly311ArgA = 0.01955missenseP18; P16**11**rs144567113c.718-29C \> TN/AT = 0.01515intronP1; P14; P17^a^variants already described \[[@CR8]\]

Patient P18 harbored 5 *FBLIM1* variants: two missense variants (rs146575757 Arg38Gln and rs114077715 Gly311Arg), two intronic (rs201006671 and rs76050903) and one synonymous (rs61733331) variant. By parental sequencing we verified that the child inherited from his mother the allele with the missense Arg38Gln, the two intronic and the synonymous variant while he inherited from his father the allele with the only Gly311Arg missense variant, found also in heterozygosis in P16. In patient P13 we identified in homozygosis the intronic variant rs187479896 and in heterozygosis the rs140170023, a synonymous variant present also in heterozygosis in other 9 patients (P2, P3, P4, P5, P6, P8, P9, P10, P13 and P15). In patient P3, in addition to the synonymous variant, the SNPs rs41310367 was also detected in heterozygosis. An intronic heterozygous variant was identified also in P11. Finally, P12 carried the missense variant Arg22His (rs540511146), P7 the variant rs766409425 and patients P1, P14, and P17 the intronic variant rs144567113.

All the 11 identified variants, especially those never described before and so orphaned of functional studies were analyzed "in silico" using specific software; results are shown in Table [2](#Tab2){ref-type="table"}. Moreover, according to dbSNP, all the variants identified are extremely rare in healthy controls examined ([supplementary table](#MOESM1){ref-type="media"}), thus enforcing their possible pathogenic roles. Table 2The in-silico analysis of the 11 FBLIM1 gene variantsNonSynonymousGlobal MAFIn Silico Analysis**rsCDS/AAAllele/MAFPP2SIFT CADDMutation Assessor**rs540511146c.65G \> A; p. R22HA/0.00011PDD LBMediumrs146575757c.113G \> A; p. R38QA/0.00391BT BLowrs114077715c.931G \> A; p. G311RA/0.01955BD LBNo, dataSynonymousGlobal MAFIn Silico Analysis (HSF)**rsCDS/AAAllele/MAFESSESEsplicing site**rs61733331c.222G \> A; p. Pro74ProA/0.00675New ESS SiteESE site brokenNASSrs140170023c.447G \> A; p.Ala149AlaA/0.01200New ESS SiteNASSIntronic VariantsGlobal MAFIn silico analysis**rsSNVsAllele/MAFNew SiteBroken SiteTRANSFAC**rs201006671c.-20-49G \> TT/0.0033Broken site for ENKTF-1rs76050903c.-20-48C \> AA/0.0033Broken site for ENKTF-1rs766409425c.541 + 13G \> AA/0.00003SF2/ASFSRp40rs187479896c.717 + 14A \> GG/0.00083rs41310367c.250 + 32C \> AT/0.0191SF2/ASF/SRp55rs144567113c.718-29C \> TT/0.01515Reference SNPs: rs; coding sequence/aminoacids: CDS/AA; Polyphen-2: PP2Sorting Intolerant from Tolerant: SIFT; Combined Annotation Dependent Depletion: CADDProbably Damaging: PD; Deleterious: D; Benign: B; Tolerated: TMinor Allele Frequency: MAF; Exonic Splicing Silencer: ESS; Exonic Splicing Enhancer: ESE

All patients presented classical features of CNO and no statistical differences between patients with or without *FBLIM1* variants were found in terms of gender prevalence, positive family history, age at onset, number of sites involved, presence of fever, arthritis and skin involvement as well as remission at the end of follow-up (Table [3](#Tab3){ref-type="table"}). Table 3Clinical presentation, laboratory data, treatment and outcome of CNO patients cohort divided following presence or absence of FBLIM1 variant. § 9 patients were lost at last follow-upPatients without FBLIM1 variants (62 patients)Patients with FBLIM1 variants (18 patients)P**Gender female**41 (66%)11 (61%)0,78**Median Age at onset**9.5 y (range 1.5--16)8.9 y (range 1,5--12)0,97**Clinical data** Fever30 (48%)4 (22%)0,06 Swelling11 (18%)7 (38%)0,1 Pain60 (96%)15 (83%)0,07**Sites**8.9 (median) Long bones46 (74%)13 (72%)1,0 Pelvis23 (37%)11 (61%)0,1 Column22 (35%)5 (27%)0,78 Clavicle16 (26%)5 (27%)1,0 Chest and ribs24 (39%)3 (16%)0,09 Foot and hands15 (24%)4 (22%)1,0 Mandible11 (18%)1 (5%)0,28 Skulls3 (5%)0 (0%)1,0**Skin involvements**11 (18%)4 (22%)0,73**Bowel involvements**3 (5%)1 (6%)1,0**Renal involvements**2 (3%)0 (0%)1,0**Laboratory data** Elevated CRP32 (52%)14 (77%)0,06 Elevated ESR41 (66%)13 (72%)0,78**Treatment** NSAIDs55 (89%)17 (94%)0,67 Steroids20 (32%)6 (33%)1,0 MTX12 (19%)3 (16%)1,0 Sulfasalazine10 (16%)3 (16%)1,0 Adalimumab3 (5%)1 (5%)1,0 Etanercept8 (13%)2 (11%)1,0 Infliximab3 (5%)2 (11%)0,31 Anakinra9 (15%)3 (17%)1,0 Neridronate2 (3%)1 (6%)1,0 Pamidronate29 (47%)8 (44%)1,0**Outcome at last follow up§** Remission without therapy32 (52%)5 (28%)0,11 Remission on therapy18 (29%)5 (28%)1,0 Active disease6 (10%)5 (28%)0,11

Discussion {#Sec4}
==========

CNO is a rare pediatric autoinflammatory bone disease and several factors such as family pedigree and syndromic monogenic forms of CNO suggest a strong genetic component. Moreover, the association between the presence of polymorphisms of the IL-10 promoter with CNO pathogenesis has been reported \[[@CR10]\]. It has been also demonstrated that mutation of the *pstpip2* gene in mice results in an autoinflammatory disease very similar to human CNO \[[@CR8]\]. However, candidate genes including *PSTPIP1*, *CARD15/NOD2*, and *IL1RN*, were not associated with CNO in humans when analyzed in small cohorts \[[@CR11], [@CR12]\].

Cox et al. recently showed that recessive mutations in *FBLIM1* contribute to the pathogenesis of CNO \[[@CR9]\]. *FBLIM1* codes for Filamin-binding LIM protein 1 (FBLP1 or migfilin), a filamin-binding protein involved in the regulation of bone remodeling \[[@CR13]\].

FBLP1 is a key regulator of the cytoskeleton, as it is recruited to cell-matrix contacts in response to adhesion and colocalizes with beta-catenin at cell-cell junctions in epithelial and endothelial cells. Through interactions with multiple binding partners, including filamin, FBLP1 links the cell adhesion structures to the actin cytoskeleton \[[@CR14]\]. FBLP1 competes with integrin β for filamin binding to promote integrin activation in neutrophils as well as bone homeostasis \[[@CR15]\]. Therefore, a mutation in the filamin-binding domain of FBLP1 may disrupt FBLP1-FLN binding, resulting in aberrant integrin activation in neutrophils and leading to sterile inflammation.

In our cohort of 80 CNO patients we found a rare coding variant of *FBLIM1* in 18 patients. Three of these variants (rs146575757, rs41310367 and rs114077715) were previously described by Cox et al. \[[@CR6]\]. The missense variant Arg38Gln (rs146575757) is in the filamin-binding domain (exon 3), so it may be causative of neutrophil activation. The second variant (rs41310367) is centrally located in the middle of an enhancer, in a STAT3 binding region and in an NR4A2 recognition site, reported to be active in several cell lines, including osteoblasts, so it may disrupt balance between osteoclasts and osteoblasts activity leading to bone remodeling. The other missense variant Gly311Arg on the last exon is localized in the third LIM domain of the protein, a small protein -protein interaction domain, containing two zinc fingers.

For the further eight variants identified in our study no literature data are available about their association with the disease or their functional impact. These variants are all rare (MAF \< 2%) in the general population, and extremely rare in the case of rs540511146 (MAF = 0.00011). The high prevalence of *FBLM1* rare variants in our CNO cohort may support a role in the pathogenesis of the disease.

Considering the intronic variants, they were predicted to possibly alter binding sites for splicing factors, in particular for the serine/arginine-rich protein (SR) specific binding sites. We observed by Human Splicing Finder a prediction in which the substitution of a single nucleotide in that specific genomic region leads to a loss and/or possible new sequence recognition by these factors and a possible creation a sequence for a new splice site. The in silico analysis and its predictions could address the research towards functional studies to verify the pathogenicity of the variants.

No statistical association was found between patients with and without *FBLIM1* gene variants, suggesting that *FBLIM1* might be considered a non-specific predisposing factor to CNO in a subgroup of patients.

Conclusions {#Sec5}
===========

CNO remains a not completely understood disease but it probably belongs to the family of autoinflammatory diseases. A unique causing gene was not found yet. However, our data seem may support the fact that some *FBLIM1* variants might increase the susceptibility to the CNO pathogenesis.
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**Additional file 1: Supplementary table**. Frequencies (Global, European, South Asian, East Asian and African) of *FBLIM1* gene variants in healthy control people (from GnomAD v2.1.1 controls dataset).
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